Abstract: Objective The aim of this study was to observe the short-term efficacy of cyberknife stereotactic radiotherapy (CSR) and transcatheter arterial chemoembolization(TACE) as the first line treatment for patients with primary liver cancer (PLC). Methods 58 patients with PLC were recruited in this study between January 2016 and May 2019, and were randomly divided into two groups. 29 patients received TACE and other 29 patients underwent TACE and CSR. Serum vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP) and AFP were detected. Results The total effective rate in TACE and CSR combination group was 82.8%, significantly higher than 58.6% in TACE-treated group (P<0.05); after treatment, serum VEGF level in the combination-treated group was (200.4±20.6) pg/ml, significantly lower than 【(326.5±31.5)pg/ml, P<0.05】, serum MMP level was (30.16±28.9)ng/L, significantly lower than 【(74.2±7.5)ng/L, P<0.05】, and serum AFP level was (632.5±60.3)μg/L, significantly lower than 【794.6±71.8)μg/L, P<0.05】 in the TACE-treated group; serum alanine aminotransferase level was (48.4±2.7)U/L, significantly higher than 【(35.4±4.0)U/L, P<0.05】 in TACE-treated group; the incidence of side effects was 44.8%, not significantly different compared to 48.3% in TACE-treated group (P>0.05). Conclusion The TACE and cyberknife stereotactic radiotherapy in treatment of patients with PLC non suitable for surgery has a good short-term clinical efficacy, which needs further investigation.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Cyberknife stereotactic radiotherapy, Therapy